AUROPHARMA

Pharmaceuticals

Aurobindo Pharma Ltd.

NSE: AUROPHARMABSE: 524804ISIN: INE406A01037
₹1,532.00
+8.60 · +0.56%
As of 24 Jul 2026
Open
₹1,512.00
High
₹1,541.00
Low
₹1,512.00
Prev Close
₹1,523.40
52W High
₹1,636.80
52W Low
₹1,016.10
Volume
4.47 L
Mkt Cap
₹89,743 Cr
Fundamentals
Valuation & profitability
Market Cap
₹89,743 Cr
P/E Ratio
24.2
EPS (TTM)
₹63.31
Book Value
₹509.00
Dividend Yield
0.33%
ROCE
14.2%
ROE
11.6%
Sales Growth
5%
Face Value
₹1.00
Company overview
Aurobindo Pharma Ltd.

It was founded in 1986 by Mr. P. V. Ramaprasad Reddy and Mr. K. Nityananda Reddy. Soon it also started its operation with a single unit manufacturing semisynthetic penicillin (SSPs) at Pondicherry, India.

It has a possible product presence in key therapeutic segments like SSPs, cephalosporins, antivirals, CNS, cardiovascular, gastroenterology, etc. The company is the market leader in semisynthetic penicillin drugs.

It has overseas branches or the representative offices which are located in Ethiopia, Tanzania, Kenya, Uganda, Italy, Ghana, Vietnam, and the UK.

It has also identified its international operations, which are catering to over 100 countries, as a significant engine of growth and expanding global network of marketing as well as manufacturing processes spread across countries like China, Japan, Brazil, Netherlands, Thailand, South Africa, UK, USA, Netherlands, Russia and many others which will further expand their international reach. Also, the subsidiaries in strategic pharmaceutical markets have positioned themselves to ride the challenges, which is powered by the strengths, and the brilliance and hard work of its global workforce, stellar track record, ever-growing infrastructure, and cost–competitiveness.

It provides various features and facilities which are listed below:

The fully integrated pharma company, Aurobindo Pharma is among the top 2 companies in India in terms of the consolidated revenues. It exports its products in over 150 countries across the world, with more than 90% of its revenues being derived from international operations.

Key highlights
Auto-generated from live data
  • Trades at a P/E of 24.2, with a return on equity (ROE) of 11.6%.
  • AUROPHARMA is trading above 3 of 5 of its key moving averages (10/20/50/100/200-DMA) — a bullish technical setup.
  • Year-to-date it is up 30.18%, and up 25.04% over the past year.
  • At ₹1,532.00 it sits about 83% of the way up its 52-week range (₹1,016.10–₹1,636.80).
  • Offers a dividend yield of 0.33%.
  • Market capitalisation stands at ₹89,743 Cr.
Price chart
Daily candles + volume · SMA 20 / 50 / 200 · stored OHLC
Shareholding pattern

Shareholding data syncs daily.

Performance
Stock returns vs Nifty 50
10D
-1.46%
Nifty -0.64%
20D
-3.95%
Nifty -1.72%
50D
+6.41%
Nifty +2.68%
100D
+13.20%
Nifty -1.14%
200D
+27.06%
Nifty -8.93%
YTD
+30.18%
Nifty -8.59%
52W
+25.04%
Nifty -7.86%
Moving averages
Simple moving averages vs current price
3/5 above · Bullish
SMA 10-Day
₹1,546.24Below
SMA 20-Day
₹1,560.50Below
SMA 50-Day
₹1,507.06Above
SMA 100-Day
₹1,424.15Above
SMA 200-Day
₹1,296.66Above
Price ranges
Where the price sits in each window
10-Day range₹1,532.00
₹1,512.00₹1,584.80
20-Day range₹1,532.00
₹1,512.00₹1,636.80
50-Day range₹1,532.00
₹1,391.00₹1,636.80
200-Day range₹1,532.00
₹1,066.80₹1,636.80
YTD range₹1,532.00
₹1,106.00₹1,636.80
52-Week range₹1,532.00
₹1,016.10₹1,636.80
Technical signals
Unfilled gaps acting as support / resistance
Unfilled Gap Up On 06 Apr, 2023 : 525.30 ~ 524.90SUPPORT
Annual financials
Revenue, profit & EPS by financial year
YearRevenueNet ProfitEPSNPM
Mar 2023₹12,792 Cr₹1,230 Cr₹21.009.62%
Mar 2022₹23,455 Cr₹2,648 Cr₹45.2011.29%
Mar 2021₹24,775 Cr₹5,335 Cr₹91.0521.53%
Mar 2021₹24,775 Cr₹5,335 Cr₹91.0521.53%
Mar 2020₹23,099 Cr₹2,831 Cr₹48.3212.26%
Mar 2020₹23,099 Cr₹2,831 Cr₹48.3212.26%
Mar 2019₹19,564 Cr₹2,365 Cr₹40.3612.09%
Mar 2019₹19,564 Cr₹2,365 Cr₹40.3612.09%
Mar 2018₹16,463 Cr₹2,423 Cr₹41.3614.72%
Mar 2017₹14,910 Cr₹2,302 Cr₹38.8915.44%
Mar 2016₹13,772 Cr₹2,025 Cr₹34.6114.7%
Mar 2015₹12,103 Cr₹1,576 Cr₹26.5513.02%
Peer comparison
Other companies in Pharmaceuticals
CompanyP/EBook ValueSales Growth
SUNPHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD.
39.1₹98.3310.1%
MARKSANS
MARKSANS PHARMA LTD.
23.8₹11.855.8%
MOREPENLAB
MOREPEN LABORATORIES LTD.
20.81₹6.4316.6%
NEULANDLAB
NEULAND LABORATORIES LTD.
23.48₹542.169.35%
GUFICBIO
Gufic BioSciences Ltd.
24.16₹10.8520.41%
DIVISLAB
DIVI'S LABORATORIES LTD.
41.01₹266.779.47%
DRREDDY
DR.REDDY'S LABORATORIES LTD.
19.73₹852.691.07%
RPGLIFE
RPG LIFE SCIENCES LTD.
17.14₹105.025.73%
GLAND
Gland Pharma Ltd
53.6₹242.00
ZYDUSLIFE
Zydus Lifesciences Ltd
8.23₹166.005%
SMSPHARMA
SMS PHARMACEUTICALS LTD.
9.58₹42.07-8.73%
CIPLA
CIPLA LTD.
15.36₹209.710.7%
Dividend history
Per share, by ex-date
Ex-Date: 17 Feb 2023₹3.00
Ex-Date: 06 Jun 2022₹4.50
Ex-Date: 18 Feb 2022₹1.50
Ex-Date: 17 Nov 2021₹1.50
Ex-Date: 27 Aug 2021₹1.50
Ex-Date: 22 Feb 2021₹1.50
Ex-Date: 23 Nov 2020₹1.25
Ex-Date: 21 Aug 2020₹1.25
Ex-Date: 17 Feb 2020₹1.75
Ex-Date: 21 Nov 2019₹1.25
Ex-Date: 15 Feb 2019₹1.25
Ex-Date: 20 Nov 2018₹1.25
Bulk & block deals
Recent large transactions
DateClientTypeQtyPrice
25 Oct 2022ISHARES CORE EMERGING MARKETS MAURITIUS COSALE2,77,213₹524.50
25 Oct 2022ISHARES CORE MSCI EMERGING MARKETS ETFPURCHASE2,77,213₹524.50
17 Oct 2022ISHARES CORE EMERGING MARKETS MAURITIUS COSALE4,35,602₹514.05
17 Oct 2022ISHARES CORE MSCI EMERGING MARKETS ETFPURCHASE4,35,602₹514.05
11 Oct 2022ISHARES CORE EMERGING MARKETS MAURITIUS COSALE3,19,465₹535.45
11 Oct 2022ISHARES CORE MSCI EMERGING MARKETS ETFPURCHASE3,19,465₹535.45
19 Sept 2022ISHARES CORE EMERGING MARKETS MAURITIUS COSALE2,17,295₹533.10
19 Sept 2022ISHARES CORE MSCI EMERGING MARKETS ETFPURCHASE2,17,295₹533.10
01 Aug 2022ISHARES INDIA INDEX MAURITIUS COMPANYSALE3,11,433₹547.00
01 Aug 2022ISHARES MSCI INDIA ETFPURCHASE3,11,433₹547.00
18 Jul 2022ISHARES INDIA INDEX MAURITIUS COMPANYSALE3,13,304₹548.75
18 Jul 2022ISHARES MSCI INDIA ETFPURCHASE3,13,304₹548.75

Fundamentals, financials & technicals sourced from niftytrader.in, cached and refreshed periodically.